Method of isolating cells for therapy and prophylaxis

Patent metadata

Field	Value
Publication number	US-10149864-B2
Application number	US-201414776288-A
Country	US
Kind code	B2
Filing date	Mar 13, 2014
Priority date	Mar 13, 2013
Publication date	Dec 11, 2018
Grant date	Dec 11, 2018

Abstract

Disclosed are methods for isolating endothelial progenitor cells (EPC). More particularly, the present invention discloses methods for isolating endothelial progenitor cells that exhibit self-renewal and differentiation capacity. The isolated cellular population of the present invention is useful in a wide range of clinical and research setting including inter alia, the in vitro or in vivo generation of endothelial cells and the therapeutic or prophylactic treatment of a range of conditions via the administration of these cells. Also facilitated is the isolation of endothelial progenitor cells for research purposes such as in vitro based screening systems for testing the therapeutic impact and/or toxicity of potential treatment or culture regimes to which these cells may be exposed to. The present invention also discloses methods for isolating mesenchymal stem cells, in particular mesenchymal stem cells of fetal and/or maternal origin. These cells are also useful in a range of in vitro and in vivo therapeutic, prophylactic and research applications.

First claim

The invention claimed is:

1. A method of isolating mammalian endothelial progenitor cells said method comprising the steps of:
(i) isolating a mammalian cellular population;
(ii) enriching for a subpopulation of the cells of step (i), which subpopulation expresses a CD45 − phenotypic profile;
(iii) enriching for a subpopulation of the CD45 − cells derived from step (ii) which express a CD34 + phenotypic profile; and
(iv) isolating the subpopulation of CD34 + cells derived from step (iii) which express a CD31 lo/− phenotypic profile, to thereby isolate the endothelial progenitor cells.

2. A method according to claim 1 , wherein the cellular preparation is a placenta-derived cellular population.

3. A method of repairing or regenerating a tissue in a subject, the method comprising contacting the tissue with an endothelial progenitor cell prepared according to claim 1 , thereby repairing or regenerating the tissue.

4. A method according to claim 3 wherein the endothelial cell or cell population is suitably isolated or derived from a histocompatible donor.

5. A method according to claim 3 , wherein the tissue is a muscle tissue, skeletal muscle tissue, cardiac tissue, neural tissue, liver tissue, pancreatic tissue, bone tissue, cartilage, renal tissue, eye tissue, skin tissue or a tissue characterized by excess cell death.

6. A method according to claim 3 , wherein the subject has or is at risk of developing a disease selected from the group consisting of myocardial infarction, congestive heart failure, peripheral vascular obstructive disease, ischemia, limb ischemia, stroke, transient ischemia, reperfusion injury, and wounds, inclusive of skin wounds, diabetic foot or ulcers, gangrene and diabetic wounds.

7. A method for enhancing angiogenesis in a subject, the method comprising contacting a tissue of the subject with an endothelial progenitor cell prepared according to claim 1 , thereby enhancing angiogenesis.

8. A method for enhancing vasculogenesis in a subject, the method comprising contacting a tissue of the subject with an endothelial progenitor cell prepared according to claim 1 , thereby enhancing vasculogenesis.

9. A method for ameliorating ischemia related tissue damage in a subject, the method comprising: (a) administering to the subject an endothelial progenitor cell prepared according to claim 1 ; and (b) enhancing angiogenesis or vasculogenesis in a tissue of the subject, thereby ameliorating ischemia related tissue damage in the subject.

10. A method according to claim 9 , wherein the ischemia related tissue damage is associated with heart failure, myocardial infarction, other ischemic heart diseases, limb ischemia, stroke, transient ischemia, or reperfusion injury.

11. A method for ameliorating heart failure in a subject, the method comprising: (a) administering to a cardiac tissue of the subject an endothelial progenitor cell prepared according to claim 1 ; and (b) enhancing angiogenesis or vasculogenesis in the cardiac tissue of the subject, thereby ameliorating heart failure in the subject.

12. A method for enhancing wound healing in a tissue of a subject, the method comprising: (a) administering to the tissue an endothelial progenitor cell prepared according to claim 1 ; and (b) increasing angiogenesis or vasculogenesis thereby increasing wound healing.

Assignees

• Univ Queensland

Inventors

• Patel Jatin
• Khosrotehrani Paul Kiarash
• Fisk Nicholas Maxwell

Classifications

• A61P9/04

  Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P27/02

  Ophthalmic agents · CPC title